Company intelligence / Profile preview

Genomate Health

Ownership: Private
Development stage: Commercial

Overview

Genomate Health’s AI-powered clinical decision support tool has demonstrated that cancer patients receiving therapies recommended by its system had a fourfold higher positive response rate compared to those treated based on single biomarker presence alone, according to results from the SHIVA01 trial. The company continues R&D and expansion efforts, including entering the US market and pursuing regulatory clearance.

Therapeutic areas: Oncology
Modalities: AI-driven clinical decision support software
Industry: Digital Health Medical Devices

Partnerships

Actively seeking partnerships with US healthcare organizations; no specific partners named yet

Beyond the preview

Go deeper on Genomate Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomate Health.

Explore the full profile